BR112021016876A2 - Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto - Google Patents

Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto

Info

Publication number
BR112021016876A2
BR112021016876A2 BR112021016876A BR112021016876A BR112021016876A2 BR 112021016876 A2 BR112021016876 A2 BR 112021016876A2 BR 112021016876 A BR112021016876 A BR 112021016876A BR 112021016876 A BR112021016876 A BR 112021016876A BR 112021016876 A2 BR112021016876 A2 BR 112021016876A2
Authority
BR
Brazil
Prior art keywords
treating
pneumonia
methods
preventing
pneumocystis
Prior art date
Application number
BR112021016876A
Other languages
English (en)
Portuguese (pt)
Inventor
A Angulo Gonzalez David
Andrew Barat Stephen
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of BR112021016876A2 publication Critical patent/BR112021016876A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112021016876A 2019-02-27 2020-02-25 Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto BR112021016876A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (1)

Publication Number Publication Date
BR112021016876A2 true BR112021016876A2 (pt) 2021-11-03

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016876A BR112021016876A2 (pt) 2019-02-27 2020-02-25 Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
KR20210133241A (ko) 2021-11-05
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
JP7581219B2 (ja) 2024-11-12
AU2020228036B2 (en) 2025-08-07
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
CN113631165A (zh) 2021-11-09
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18
EA202192344A1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
NZ800220A (en) Methods of treating heart failure by administering omecamtiv mecarbil
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
AR119159A1 (es) Tratamientos de angioedema
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
PE20241327A1 (es) Tratamiento de trastornos hepaticos con un agonista del thr-beta
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2025005392A (es) Composicion farmaceutica que comprende un inhibidor de aak1
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
BR112021016876A2 (pt) Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
BR112023017116A2 (pt) Composição farmacêutica combinada contendo inibidor de cdk4/6 e uso da mesma
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
AR131842A1 (es) Métodos para tratar gliomas
BR112019000813A2 (pt) formas sólidas de inibidor de ttk
BR112022000734A2 (pt) Método para tratar câncer em um paciente, uso de composto 1, e, composto 1

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]